Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2024 08:05 ET | Source: MaxCyte, Inc

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
November 06, 2024 16:05 ET | Source: MaxCyte, Inc

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
October 31, 2024 08:05 ET | Source: MaxCyte, Inc

MaxCyte to Participate in Two Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
October 15, 2024 08:05 ET | Source: MaxCyte, Inc

MaxCyte Appoints Cynthia Collins to its Board of Directors

ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
October 11, 2024 08:05 ET | Source: MaxCyte, Inc

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
October 10, 2024 08:05 ET | Source: MaxCyte, Inc

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
September 16, 2024 02:00 ET | Source: MaxCyte, Inc

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform...
September 05, 2024 16:05 ET | Source: MaxCyte, Inc

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
August 06, 2024 16:05 ET | Source: MaxCyte, Inc

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...
July 09, 2024 16:05 ET | Source: MaxCyte, Inc

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...